Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Jun;72(6):994-998.
doi: 10.1111/all.13103. Epub 2017 Mar 13.

Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

A Zanichelli  1 , M Maurer  2 , W Aberer  3 , T Caballero  4 , H J Longhurst  5 , L Bouillet  6 , V Fabien  7 , I Andresen  8 ; IOS Study Group
Collaborators, Affiliations
Observational Study

Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

A Zanichelli et al. Allergy. 2017 Jun.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Allergy. 2018 Sep;73(9):1929. doi: 10.1111/all.13259. Allergy. 2018. PMID: 30168183 Free PMC article. No abstract available.

Abstract

The Icatibant Outcome Survey (IOS) is an observational study monitoring safety and effectiveness of icatibant in the real-world setting. We analyzed safety data from 3025 icatibant-treated attacks in 557 patients (enrolled between July 2009 and February 2015). Icatibant was generally well tolerated. Excluding off-label use and pregnancy, 438 patients (78.6%) did not report adverse events (AEs). The remaining 119 (21.4%) patients reported 341 AEs, primarily gastrointestinal disorders (19.6%). Of these, 43 AEs in 17 patients (3.1%) were related to icatibant. Serious AEs (SAEs) occurred infrequently. A total of 143 SAEs occurred in 59 (10.6%) patients; only three events (drug inefficacy, gastritis, and reflux esophagitis) in two patients were considered related to icatibant. Notably, no SAEs related to icatibant occurred in patients with cardiovascular disease, nor in those using icatibant at a frequency above label guidelines. Additionally, no major differences were noted in AEs occurring in on-label vs off-label icatibant users.

Keywords: angioedema; icatibant; real-world; safety.

PubMed Disclaimer

References

    1. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M et al. Icatibant, a new bradykinin‐receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532–541. - PMC - PubMed
    1. Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D et al. Randomized placebo‐controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST‐3 trial. Ann Allergy Asthma Immunol 2011;107:529–537. - PubMed
    1. Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A et al. Repeat treatment of acute hereditary angioedema attacks with open‐label icatibant in the FAST‐1 trial. Clin Exp Immunol 2014;177:544–553. - PMC - PubMed
    1. Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A et al. Open‐label, multicenter study of self‐administered icatibant for attacks of hereditary angioedema. Allergy 2014;69:305–314. - PubMed
    1. Bas M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST‐2 open‐label study. Allergy 2013;68:1452–1459. - PubMed

Publication types